Pharmaceuticals and Healthcare Reports Japan Dyslipidemia Market Zum Anzeigen klicken
  • Kommentare

Pharmaceuticals and Healthcare Reports

Japan Dyslipidemia Market

Veröffentlicht am in "Gesundheit & Fitness, Gesundheit & Fitness", Sprache — English. 3 Seiten.
The launch of the proprotein convertase subtilisin/kexin type 9 (PCSK9) biologics and the cholesteryl ester transfer protein (CETP) inhibitors will reshape the sales landscape of the dyslipidemia market moving forward. Mehr anzeigen
KOSTENLOSES Abonnement